Medical (incl. medical device & pharma), US Foreign Corrupt Practices Act & Dodd Frank - Written by on Tuesday, November 23, 2010 3:23 - 0 Comments

Pharmaceutical businesses and the stark warning from the SFO

Print Friendly

Barry and Richard write on FCPA Compliance and Ethics Blog about the thinly veiled warning recently issued by the Director of the Serious Fraud Office, Richard Alderman to the pharmaceutical sector.

It has been well publicised that the pharmaceutical sector has been under increasing scrutiny from US regulators. Mr. Alderman spoke at a UK pharmaceutical conference about the industry, the Bribery Act and the SFO’s close co-operation with the US Department of Justice which is involved in a Foreign Corrupt Practices Act investigation into the pharmaceutical sector in the US.

Share Button

Comments are closed.

Brought to you by...

Barry Vitou &
Richard Kovalevsky Q.C.

The views expressed on this website are those of Barry Vitou & Richard Kovalevsky QC and/or our guest authors from time to time. Please see our terms of use

in association with...

Our Tweets

Friday, August 11, 2017 20:40

Former DoJ chief Sally Yates on being fired by Trump via @FT

Sunday, June 11, 2017 8:18

Opinion: As debate shifts from future of SFO to future of Theresa May we say: At last, fund the SFO properly.

Friday, June 9, 2017 12:21

SFO cat uses up another life! SFO set to stay after Theresa May's authority is seriously undermined.

Tuesday, May 23, 2017 11:44

Opinion: Conservatives must answer two basic questions about the plan to merge the SFO into the NCA

Thursday, May 18, 2017 21:07

Announcement of SFO merger into the NCA must be followed with detailed plans and assurances to SFO plans now